Missing Script

Get updates

MS-N125 · Supportive care · Human evidence · Appraised 24 October 2026

Does manual lymphatic drainage (MLD) add benefit to compression, exercise and education for established breast-cancer-related lymphedema?

Evidence at a glance

  • Evidence label: No clear added volume benefit over decongestive care
  • Benefit: Manual lymphatic drainage may improve feelings such as heaviness or discomfort for some people, but larger controlled evidence does not show extra arm-volume reduction.
  • Certainty: Moderate confidence that adding MLD to a well-delivered decongestive program does not materially improve volume for most established cases.
  • Risk: Usually gentle, but active infection, suspected clot, unstable heart failure and fragile tissue require medical assessment.

What was studied

Population and design: A 54-person randomized trial compared bandaging and exercise with or without MLD. The larger EFforT-BCRL trial included 194 people with chronic breast-cancer-related lymphedema.

Studied regimen: The smaller trial delivered 15 weekday sessions over 3 weeks. EFforT gave all groups standard decongestive lymphatic therapy, then compared fluoroscopy-guided MLD, traditional MLD and placebo MLD over 3 weeks with maintenance to 6 months.

What the evidence found

In the 54-person trial, both groups improved, with no between-group difference in volume, QuickDASH or Lymph-ICF; discomfort and heaviness favored MLD. In EFforT, excess-arm-volume reduction at 6 months was 5.3, 5.2 and 5.4 percentage points in the guided, traditional and placebo groups, with no clinically important difference. Secondary outcomes also did not distinguish the groups.

How to interpret it

MLD is difficult to blind and technique varies. These trials address added value within a multimodal program, not whether compression, exercise, skin care or specialist rehabilitation work. Results do not apply to every anatomical pattern or early swelling.

Practical safety context

Seek urgent assessment for redness, warmth, fever, sudden swelling, chest symptoms or suspected thrombosis. MLD is generally deferred during acute cellulitis and requires clinician guidance with heart or kidney failure, wounds, fragile irradiated skin or active clot. It should be delivered by a trained lymphedema therapist.

Questions for the care team

  • Is the symptom or complication being caused by something that needs conventional treatment first?
  • Would blood counts, anticoagulants, infection risk, surgery, radiation effects or implanted devices change whether this is safe?
  • What outcome will we track, and when should we stop if it is not helping?

Funding and conflicts

Funding and conflicts differed by trial; EFforT’s full report provides sponsor and author disclosures.

Sources

Last literature search: 24 October 2026. Record appraisal: 24 October 2026. This page is educational and does not replace individualized medical advice. Symptom improvement must not be interpreted as evidence of tumor response, delayed recurrence or longer survival.